Halozyme Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.4%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$1.9Bnext fiscal year
FY EPS (est.)
$8.58next fiscal year
Monitoring Framework
Key Performance Indicators
Royalty Revenue Quarterly240.7MTarget: $1.130 billion to $1.170 billion
Total Revenue Quarterly376.7MTarget: $1.710 billion to $1.810 billion
Adjusted EBITDA Quarterly229.5MTarget: $1.125 billion to $1.205 billion
Watch Items
- Hypercon Phase I Clinical StartsTrigger: First half of 2027Action: Monitor partner progress and initiation of Phase I trials using the Hypercon hyperconcentration technology.
- Medicare Drug Price Negotiation Program (IRA) ImpactTrigger: IPAY 2029 Proposed RuleAction: Assess potential long-term royalty impacts; current projections indicate zero to minimal impact through at least 2035.
Research as of 2 Sep 2026